Teva Pharmaceutical Industries Limited's (TEVA) "Hold" Rating Reiterated at Maxim Group

Lucy Hill
August 5, 2017

Apart from lower prices, Teva said that the company's quarter was hurt by lower volume and the market over-saturation of generic drugs. Sii Investments Inc. WI now owns 6,739 shares of the company's stock valued at $214,000 after buying an additional 25 shares during the last quarter. Lincluden Management Ltd. increased its position in Teva Pharmaceutical Industries Limited by 7.8% in the fourth quarter. The First City Capital Management Inc holds 26,570 shares with $963,000 value, up from 11,935 last quarter.

Teva Pharmaceutical Industries (TEVA) opened at 23.75 on Tuesday. Whereas, in last 21 trading days (one month) was surged -27.39% and slashed in last 63 trading days (quarter) of -23.06%. The correct version of this news story can be viewed at On Monday, December 7 the stock rating was initiated by Mizuho with "Buy".

Generics comprise the lion's share of Teva's sales, and will likely become more important as branded drugs like Copaxone face competition. Institutional investors own 56.20% of the company's stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. It turned negative, as 10 investors sold Black Diamond Inc shares while 21 reduced holdings. Teva Pharmaceutical Industries Limited (TEVA) has made its way to a 12-month decline of -55.67%. Beta factor, which measures the riskiness of the security, was observed as 0.46. The firm shares 50 day moving average were calculated -32.54%. Teva Pharmaceutical Industries Limited also saw some unusual options trading on Thursday. (NASDAQ:MEET) lands the stock on today's most volatile list. This is an increase of approximately 864% compared to the typical daily volume of 6,922 put options.

For the Current Quarter, the growth estimate for Teva Pharmaceutical Industries Limited is -15.2%, while for the Next Quarter the stock growth estimate is -4.6%.

RBI asks banks to lower rates further
In the previous meeting of the MPC in June, the policy rate was left unchanged at 6.25%. Lowering of the repo rate by RBI is a signal to lenders to bring down their rates.

Israeli drugs group Teva Pharmaceutical Industrial Industries reported a steeper than expected 18.4 percent drop in second-quarter earnings on Thursday, due to weaker prices in the United States, and cut its interim dividend by 75 percent. The value of the investment in Teva Pharmaceutical Industries went from $1,615,000 to $1,830,000 a change of 13.3% since the last quarter. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter a year ago, the firm posted $1.25 earnings per share.

WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of global copyright laws.

Several other research analysts have also issued reports on TEVA. The current share price indicates that stock is -57.43% away from its one year high and is moving -13.93% ahead of its 52-week low. They now have a $21.00 target price on the stock, down from their prior target price of $37.00. Country Club Trust Company n.a. raised its stake in Teva Pharmaceutical Industries by 5.7% in the first quarter. A rating of 4 or 5 would represent a Sell recommendation.

In total: Teva's primary businesses are performing poorly, the company is still searching for a new CEO, it carries a mountain of debt, and its largest shareholder now has the green light to look for an exit. In specialty medicines, Teva has treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system.

Other reports by TheDailyFarc

Discuss This Article